GLP-1 and obesity surgery: benefits depend on treatment timing

Three clinical situations, not a single strategy

The review brings together 27 studies on GLP-1 receptor agonists around bariatric surgery. Ten address treatment before surgery, four address early postoperative treatment, and thirteen address treatment after insufficient weight loss or weight regain. Thirteen studies were included in the efficacy meta-analyses.

This distinction matters: losing more weight before surgery, increasing postoperative weight loss, and treating weight regain are different goals. A favorable result in one of these situations does not automatically validate the others.

Before surgery, the starting point changes the interpretation

Preoperative treatment appears to improve weight loss before surgery. However, at twelve months after surgery, weight loss expressed as a percentage of body weight at the time of surgery is 2.85 percentage points lower in the group that received the medication than in the group without preoperative treatment.

This finding is not enough to conclude that the medication worsens the overall outcome. The calculation starts from the weight measured at surgery, so it does not count weight already lost beforehand. The abstract does not establish the total weight-loss benefit from the start of care.

After surgery, a possible but variable benefit

Adding a GLP-1 around one month after surgery is associated, at six months, with an additional loss of 3.62 percentage points of total body weight compared with controls. However, the limited number of studies on early postoperative use warrants caution against making this a routine strategy.

After insufficient weight loss or weight regain, four randomized trials report an additional loss of 10.30 percentage points at the final assessment compared with placebo or usual care. The confidence interval ranges from 6.40 to 14.20 points. Results vary substantially between trials, and their duration is not specified in the abstract: this average is not an individual prediction.

Digestive side effects remain a practical limitation

In studies that clearly report event counts, pooled rates are 25.3% for nausea, 19.0% for constipation, 9.2% for diarrhea, and 8.6% for vomiting. These figures do not measure the excess risk compared with a control group.

Serious adverse events are described as uncommon. However, the abstract does not allow a precise assessment of long-term safety, differences between drugs, or interactions. These findings alone therefore do not justify changing treatment without involving the healthcare team.

What we can take away

The strongest signal concerns treatment for insufficient weight loss or weight regain after surgery. The review does not demonstrate that routinely adding a GLP-1 before or just after surgery is better for everyone.